DOI:
10.1055/s-00000069
Seminars in Liver Disease
LinksClose Window
References
Fakhouri F, Hourmant M, Campistol JM. et al.
Terminal complement inhibitor eculizumab in adult patients with atypical hemolytic uremic syndrome: a single-arm, open-label trial.
Am J Kidney Dis 2016;
68 (01) 84-93
We do not assume any responsibility for the contents of the web pages of other providers.